ES2173422T3 - Disociacion de treo-metilfenidato. - Google Patents

Disociacion de treo-metilfenidato.

Info

Publication number
ES2173422T3
ES2173422T3 ES97906283T ES97906283T ES2173422T3 ES 2173422 T3 ES2173422 T3 ES 2173422T3 ES 97906283 T ES97906283 T ES 97906283T ES 97906283 T ES97906283 T ES 97906283T ES 2173422 T3 ES2173422 T3 ES 2173422T3
Authority
ES
Spain
Prior art keywords
methylphenidate
disreciation
treo
threo
proceeds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97906283T
Other languages
English (en)
Inventor
Hooshang Shahriari Zavareh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech Pharma Europe Ltd
Original Assignee
Medeva Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9604943.2A external-priority patent/GB9604943D0/en
Application filed by Medeva Europe Ltd filed Critical Medeva Europe Ltd
Application granted granted Critical
Publication of ES2173422T3 publication Critical patent/ES2173422T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • B01D9/0013—Crystallisation cooling by heat exchange by indirect heat exchange

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Thermal Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Read Only Memory (AREA)

Abstract

UN PROCEDIMIENTO PARA PREPARAR EN UNA CANTIDAD SUSTANCIAL EL ENANTIOMERO INDIVIDUAL D - TREO - METILFENIDATO, EL CUAL SE REALIZA MEDIANTE UNA RESOLUCION CLASICA DE LA SAL UTILIZANDO ACIDO (-) METOXIACETICO.
ES97906283T 1996-03-08 1997-03-07 Disociacion de treo-metilfenidato. Expired - Lifetime ES2173422T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9604943.2A GB9604943D0 (en) 1996-03-08 1996-03-08 Resolution
US1698696P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
ES2173422T3 true ES2173422T3 (es) 2002-10-16

Family

ID=26308891

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97906283T Expired - Lifetime ES2173422T3 (es) 1996-03-08 1997-03-07 Disociacion de treo-metilfenidato.

Country Status (11)

Country Link
EP (1) EP0885191B1 (es)
JP (1) JP4138005B2 (es)
KR (1) KR100459149B1 (es)
AT (1) ATE212336T1 (es)
AU (1) AU700836B2 (es)
CA (1) CA2243542C (es)
DE (1) DE69710051T2 (es)
DK (1) DK0885191T3 (es)
ES (1) ES2173422T3 (es)
PT (1) PT885191E (es)
WO (1) WO1997032851A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
GB9700912D0 (en) 1997-01-17 1997-03-05 Chiroscience Ltd Resolution
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US6100401A (en) * 1998-04-20 2000-08-08 Novartris Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
US6162919A (en) * 1998-12-03 2000-12-19 Novartis Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
US7229557B2 (en) 2004-02-04 2007-06-12 Konec, Inc. Method to separate stereoisomers
WO2010128517A1 (en) 2009-05-07 2010-11-11 Malladi Drugs & Pharmaceuticals Ltd. Improved process for the preparation of d-threo-ritalinic acid hydrochloride by resolution of dl-threo-ritalinic acid using chiral carboxylic acid
MX2021000431A (es) 2011-03-23 2022-10-28 Ironshore Pharmaceuticals & Dev Inc Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957880A (en) * 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US4196303A (en) * 1978-03-20 1980-04-01 Scm Corporation d-Isomenthoxyacetic acid
JPS5538363A (en) * 1978-09-13 1980-03-17 Yoshitomi Pharmaceut Ind Ltd Preparation of optically active n-mercaptoacyl-imino acid

Also Published As

Publication number Publication date
JP2000506162A (ja) 2000-05-23
DK0885191T3 (da) 2002-05-06
CA2243542C (en) 2003-02-18
KR19990087441A (ko) 1999-12-27
DE69710051T2 (de) 2002-08-14
CA2243542A1 (en) 1997-09-12
JP4138005B2 (ja) 2008-08-20
PT885191E (pt) 2002-06-28
DE69710051D1 (de) 2002-03-14
MX202728B (es) 2001-06-29
WO1997032851A1 (en) 1997-09-12
EP0885191B1 (en) 2002-01-23
MX9807266A (es) 1999-08-31
AU2102497A (en) 1997-09-22
EP0885191A1 (en) 1998-12-23
ATE212336T1 (de) 2002-02-15
AU700836B2 (en) 1999-01-14
KR100459149B1 (ko) 2005-06-10

Similar Documents

Publication Publication Date Title
ES2173422T3 (es) Disociacion de treo-metilfenidato.
NO20000935L (no) Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei
DE59606920D1 (de) Chirale methylphenyloxazolidinone
PT828717E (pt) Metodo de preparacao de 3-haloalquil-1h-pirazoles
LTIP1891A (en) Method for the purification of taxoides
BR0209554A (pt) Métodos para a preparação de um composto, e composto
EE04491B1 (et) (+)-nortsisapriidi kasutamine
BR0007643A (pt) Processo para obter ésteres de (nitroximetil) fenila de derivados de aspirina, e, (hidroximetil) feniléter de derivados de aspirina
GB9826540D0 (en) Process
GR3030113T3 (en) Ultrasensitive process for assaying cardiac troponine i
IL146811A0 (en) Novel method for preparing benzoperhydroisoindole compounds
DK0683168T3 (da) Fremgangsmåde til fremstilling af 2-methylspiro(1,3-oxathiolan-5,3')quinuclidin
DE60003807D1 (de) Enantiomere von mercaptolactonen und verfahren zu ihrer herstellung
IL133923A0 (en) Method for preparing 3-cyano-2,4-dihalogen-5-fluoro-benzoic acid
FI861527A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten dibentso/b,e/oksepiinietikkahappojohdannaisten valmistamiseksi.
FI900129L (fi) Menetelmä 3-(N-fenyyliasetyyliaminopiperidiini)-2,6-dionin valmistamiseksi
EA199900282A2 (ru) Способ получения феноксифенилсульфонилгалогенидов
BG104964A (bg) Подобрен метод за получаване на фармацевтично ценни норбензоморфанови производни
FR2795728B1 (fr) Procede de preparation de l'acide lysergique
AU5681100A (en) Method for producing 4,6-dichloropyrimidine
GR890100208A (el) Νέα μέθοδος παρασκευής παραγώγων ιμιδαζοπυριδινών.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 885191

Country of ref document: ES